US2007172877A1PendingUtilityA1
Methods for preventing cattle reproductive diseases
Est. expiryApr 21, 2023(expired)· nominal 20-yr term from priority
A61P 31/12A61P 31/22A61P 31/04C12N 2710/16734A61K 2039/552C12N 2760/18634C12N 2770/24334A61K 39/0225A61K 39/245C12N 2760/18534A61K 2039/70A61K 2039/55A61K 39/105A61P 15/04A61P 15/06A61K 39/12A61P 15/00A61K 2039/5254
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj - prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo - bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.
Claims
exact text as granted — not AI-modified1 . A method of preventing infection in an animal that is nursing a pregnant animal, wherein the pregnant animal has been vaccinated prior to breeding with a therapeutically effective amount of a first vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1), comprising administering to the nursing animal a therapeutically effective amount of a second vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1).
2 . A method of preventing infection in an animal that is nursing a pregnant animal, wherein the pregnant animal has been vaccinated prior to breeding with a therapeutically effective amount of a first vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1), comprising administering to the nursing animal a therapeutically effective amount of a second vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1) and at least one antigen selected from the group consisting of: Bovine Viral Diarrhea Virus (BVDV); a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira Bratislava , and Campylobacter fetus.
3 . The method of claim 1 , wherein said second vaccine composition further comprises an adjuvant.
4 . The method of claim 1 , wherein said pregnant animal is a cow or a heifer.
5 . The method of claim 1 , wherein said nursing animal is a calf nursing a pregnant cow.
6 . The method of claim 1 , wherein said second vaccine composition is administered intramuscularly.
7 . The method of claim 1 , wherein said second vaccine composition is administered subcutaneously.
8 . The method of claim 1 , wherein said second vaccine composition contains from about 10 2 to about 10 10 TCID 50 units per dose of each virus.
9 . The method of claim 1 , wherein the amount of said second vaccine composition administered is from about 0.1 to about 5.0 ml per dose.
10 . The method of claim 1 , wherein the amount of said second vaccine composition administered is about 5 ml per dose.
11 . The method of claim 1 , wherein the amount of said second vaccine composition administered is about 2 ml per dose.
12 . The method of claim 2 , wherein said second vaccine further comprises an adjuvant.
13 . The method of claim 2 , wherein said pregnant animal is a cow or a heifer.
14 . The method of claim 2 , wherein said nursing animal is a calf nursing a pregnant cow.
15 . The method of claim 2 , wherein said second vaccine composition is administered intramuscularly.
16 . The method of claim 2 , wherein said second vaccine composition is administered subcutaneously.
17 . The method of claim 2 , wherein said second vaccine composition contains from about 10 2 to about 10 10 TCID 50 units per dose of each virus.
18 . The method of claim 2 , wherein the amount of said second vaccine composition administered is from about 0.1 to about 5.0 ml per dose.
19 . The method of claim 2 , wherein the amount of said second vaccine composition administered is about 5 ml per dose.
20 . The method of claim 2 , wherein the amount of said second vaccine composition administered is about 2 ml per dose.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.